Several multinational drug makers, including GlaxoSmithKline and Merck Sharp and Dohme, are set to provide more AIDS prevention and treatment services in China. About 1 million HIV patients have been registered in China, according to the Ministry of Health, and the Chinese government has accelerated the nationalization of HIV/AIDS drug production capacity. It has also negotiated with international pharmaceutical companies in an effort to secure AIDS drugs at lower prices. MSD has cooperated with the government in medical training and public education programs on preventing HIV/AIDS. "Only a comprehensive prevention and treatment plan, funded at least partially by the government, along with the improvement of fundamental medical infrastructure and proper medical training, can control the epidemic situation," said Qu Wanwan, chief inspector of the marketing department of MSD China.

Back to other CDC news for April 22, 2003

Previous Updates | Search the CDC archive